Jay Bhatnagar

Jay Bhatnagar

Auto-generated profile, based on publicly available information

Jay Bhatnagar

Center for Neurologic Diseases, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA 92037, USA

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 July 2026 in Science Advances
Verified
Journal Article
Open access
HHHuijie Huang
Huijie Huang
CSChristina Huan Shi
Christina Huan Shi
WYWenqi Yang
Wenqi Yang
JPJuan Pina-Crespo
Juan Pina-Crespo
JBJay Bhatnagar
Jay Bhatnagar
THTimothy Y. Huang
Timothy Y. Huang
A role for the trafficking receptor SORLA (Sortilin-related receptor containing LDLR class A repeats) in reducing Aβ levels has been well established; however, relatively little is known with respect to whether and how SORLA can potentially affect tau pathology in vivo. Here, we show that transgenic SORLA up-regulation (SORLA TG) can attenuate pathological effects in aged PS19 (P301S tau) mouse brain, including tau phosphorylation and seeding, ventricle dilation, synapse loss, long-term potentiation (LTP) impairment, and glial hyperactivation. Proteomic analysis indicates attenuation of PS19 profiles in PS19/SORLA TG hippocampus, including pathological changes in synapse-related proteins and key drivers of synaptic dysfunction such as ApoE and C1q. Single-nucleus RNA sequencing analysis reveals suppression of PS19 signatures with SORLA up-regulation and identifies a previously unrecognized involvement of Sema4D-PlexinB1/B2 signaling in glial pathology. In contrast, SORLA deletion exacerbates tau seeding and aggregation, glial hyperactivation, and PlxnB1/B2 induction in PS19 hippocampus. These results indicate that SORLA confers neuroprotection against tau toxicity in the PS19 mouse brain.